Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8N135
UPID:
LGI4_HUMAN
Alternative names:
LGI1-like protein 3; Leucine-rich glioma-inactivated protein 4
Alternative UPACC:
Q8N135; B2RN53; B9EGS7; Q5M8T1
Background:
Leucine-rich repeat LGI family member 4, also known as LGI1-like protein 3 or Leucine-rich glioma-inactivated protein 4, plays a crucial role in the Schwann cell signaling pathways. These pathways are instrumental in axon segregation and myelin formation, processes vital for the proper functioning of the nervous system.
Therapeutic significance:
The protein is linked to Arthrogryposis multiplex congenita 1, a severe neurogenic condition with myelin defects leading to multiple joint contractures and, in many cases, prenatal mortality. Understanding the role of Leucine-rich repeat LGI family member 4 could open doors to potential therapeutic strategies for this debilitating disease.